Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bicara Therapeutics Q3 2026 Results: Net Loss of $71.2M, Loss Widens

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing ficerafusp alfa, reporting 66,387,197 shares of common stock outstanding as of November 3, 2026. The company continues to incur significant financial losses and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-71.2-36.3
Net income-71.2-36.3
EPS (diluted, $ a share)$-1.04$-0.67

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BCAX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bicara Therapeutics Inc.: key numbers

Share price
$9.60Close, Nov 17
Market cap
$637M
Shares outstanding
66.39MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bicara Therapeutics Inc.

All →
7:52 AM ET 8-K
Financial Results

Bicara Therapeutics Financial Results

Bicara Therapeutics reported Q3 2026 financial results, ending the period with $442.3 million in cash and marketable securities. The company achieved substantial enrollment in its FORTIFI-HN01 pivotal trial for head and neck cancer, with topline interim results expected in mid-2027. Management expects current cash reserves to fund operations into the first half of 2029.

Term
Q3 2026

“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need.”

Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer

“Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology.”

Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.